{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:01:33Z","timestamp":1767942093013,"version":"3.49.0"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jns.2025.125705","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T07:15:32Z","timestamp":1766646932000},"page":"125705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on \u201cwearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab\u201d"],"prefix":"10.1016","volume":"480","author":[{"given":"Bhumesh","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leelabati","family":"Toppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Biradar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2025.125705_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2025.125652","article-title":"Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab","volume":"479","author":"Gelissen","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2025.125705_bb0010","doi-asserted-by":"crossref","first-page":"1079945","DOI":"10.1080\/23311908.2015.1079945","article-title":"The impact of symptom stability on time frame and recall reliability in CFS","volume":"2","author":"Evans","year":"2015","journal-title":"Cogent Psychology."},{"issue":"3","key":"10.1016\/j.jns.2025.125705_bb0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000371757","article-title":"Editorial: subjective perceptions of memory functioning in old age - nature, correlates, and developmental trajectories","volume":"61","author":"H\u00fcl\u00fcr","year":"2015","journal-title":"Gerontology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25023275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:19:08Z","timestamp":1767935948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25023275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":3,"alternative-id":["S0022510X25023275"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.125705","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on \u201cwearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.125704","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125705"}}